Cognoa leverages machine learning and patient reported outcomes to revolutionize how parents and clinicians screen and support child development. Cognoa gives parents peace of mind and helps them take the right action at the right time to best support their child's development. Cognoa's assessment has been used by 300,000 families and has been validated in multiple scientific clinical studies. It is based on more than five years of clinical research and validation studies led by Dennis Wall, PhD, at prominent institutions including Harvard Medical School and Stanford Medical School.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
03/28/17 | $11,600,000 |
Morningside Venture | undisclosed |